These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

676 related articles for article (PubMed ID: 34519567)

  • 21. Psychedelics for treatment resistant depression: are they game changers?
    Kalfas M; Taylor RH; Tsapekos D; Young AH
    Expert Opin Pharmacother; 2023; 24(18):2117-2132. PubMed ID: 37947195
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The psychedelic call: analysis of Australian Poisons Information Centre calls associated with classic psychedelics.
    Wilkes R; Roberts DM; Liknaitzky P; Brett J
    Clin Toxicol (Phila); 2024 Apr; 62(4):242-247. PubMed ID: 38753585
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Illicit use of LSD or psilocybin, but not MDMA or nonpsychedelic drugs, is associated with mystical experiences in a dose-dependent manner.
    Lyvers M; Meester M
    J Psychoactive Drugs; 2012; 44(5):410-7. PubMed ID: 23457892
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Serotonergic Psychedelics: A Comparative Review of Efficacy, Safety, Pharmacokinetics, and Binding Profile.
    Holze F; Singh N; Liechti ME; D'Souza DC
    Biol Psychiatry Cogn Neurosci Neuroimaging; 2024 May; 9(5):472-489. PubMed ID: 38301886
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Contribution of serotonin 5-HT
    Ibi D
    Nihon Yakurigaku Zasshi; 2023 May; 158(3):229-232. PubMed ID: 36990794
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Psychedelic therapy for depressive symptoms: A systematic review and meta-analysis.
    Ko K; Kopra EI; Cleare AJ; Rucker JJ
    J Affect Disord; 2023 Feb; 322():194-204. PubMed ID: 36209780
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Addressing the Current Knowledge and Gaps in Research Surrounding Lysergic Acid Diethylamide (LSD), Psilocybin, and Psilocin in Rodent Models.
    Ezeaka UC; Kim HJJ; Laprairie RB
    Curr Top Med Chem; 2023; 23(23):2232-2241. PubMed ID: 37409550
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Ethopharmacological evaluation of antidepressant-like effect of serotonergic psychedelics in C57BL/6J male mice.
    Takaba R; Ibi D; Yoshida K; Hosomi E; Kawase R; Kitagawa H; Goto H; Achiwa M; Mizutani K; Maeda K; González-Maeso J; Kitagaki S; Hiramatsu M
    Naunyn Schmiedebergs Arch Pharmacol; 2024 May; 397(5):3019-3035. PubMed ID: 37874338
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The effects of Lysergic Acid Diethylamide (LSD) on the Positive Valence Systems: A Research Domain Criteria (RDoC)-Informed Systematic Review.
    Pouyan N; Younesi Sisi F; Kargar A; Scheidegger M; McIntyre RS; Morrow JD
    CNS Drugs; 2023 Dec; 37(12):1027-1063. PubMed ID: 37999867
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Psychedelic drugs for psychiatric disorders.
    da Costa SC; Oesterle T; Rummans TA; Richelson E; Gold M
    J Neurol Sci; 2022 Sep; 440():120332. PubMed ID: 35841696
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Sustained effects of single doses of classical psychedelics in humans.
    Knudsen GM
    Neuropsychopharmacology; 2023 Jan; 48(1):145-150. PubMed ID: 35729252
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Psychedelics in the treatment of unipolar mood disorders: a systematic review.
    Rucker JJ; Jelen LA; Flynn S; Frowde KD; Young AH
    J Psychopharmacol; 2016 Dec; 30(12):1220-1229. PubMed ID: 27856684
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Psychedelic Therapy: A Primer for Primary Care Clinicians-Historical Perspective and Overview.
    Tabaac BJ; Shinozuka K; Arenas A; Beutler BD; Cherian K; Evans VD; Fasano C; Muir OS
    Am J Ther; 2024 Mar-Apr 01; 31(2):e97-e103. PubMed ID: 38518266
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Therapeutic effects of classic serotonergic psychedelics: A systematic review of modern-era clinical studies.
    Andersen KAA; Carhart-Harris R; Nutt DJ; Erritzoe D
    Acta Psychiatr Scand; 2021 Feb; 143(2):101-118. PubMed ID: 33125716
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Serotonergic psychedelics LSD & psilocybin increase the fractal dimension of cortical brain activity in spatial and temporal domains.
    Varley TF; Carhart-Harris R; Roseman L; Menon DK; Stamatakis EA
    Neuroimage; 2020 Oct; 220():117049. PubMed ID: 32619708
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Human behavioral pharmacology of psychedelics.
    Strickland JC; Johnson MW
    Adv Pharmacol; 2022; 93():105-132. PubMed ID: 35341564
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Psychedelic microdosing benefits and challenges: an empirical codebook.
    Anderson T; Petranker R; Christopher A; Rosenbaum D; Weissman C; Dinh-Williams LA; Hui K; Hapke E
    Harm Reduct J; 2019 Jul; 16(1):43. PubMed ID: 31288862
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Therapeutic Potential of Psychedelics in Treatment of Psychiatric Disorders, Part 2: Review of the Evidence.
    Hosanagar A; Cusimano J; Radhakrishnan R
    J Clin Psychiatry; 2021 Feb; 82(3):. PubMed ID: 33988930
    [No Abstract]   [Full Text] [Related]  

  • 39. Serotonergic Psychedelics: Experimental Approaches for Assessing Mechanisms of Action.
    Canal CE
    Handb Exp Pharmacol; 2018; 252():227-260. PubMed ID: 29532180
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A Meta-Analysis of Placebo-Controlled Trials of Psychedelic-Assisted Therapy.
    Luoma JB; Chwyl C; Bathje GJ; Davis AK; Lancelotta R
    J Psychoactive Drugs; 2020; 52(4):289-299. PubMed ID: 32529966
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 34.